Discontinued — last reported Q4 '25
Biogen Other Comprehensive Income (Loss) decreased by 100.4% to -$1.80M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
A large positive value suggests favorable currency or market movements, while a large negative value indicates potential future volatility in equity.
This represents the aggregate of all items of other comprehensive income or loss, which are excluded from net income und...
Standardized across all public companies under GAAP/IFRS reporting requirements.
tmusz_other_comprehensive_income_loss| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$500.00K | $100.00K | -$9.70M | -$8.30M | -$1.00M | $5.70M | -$4.50M | $14.50M | $0.00 | $0.00 | $0.00 | $0.00 | $571.20M | $489.80M | -$1.80M |
| QoQ Change | — | +120.0% | <-999% | +14.4% | +88.0% | +670.0% | -178.9% | +422.2% | -100.0% | — | — | — | — | -14.3% | -100.4% |
| YoY Change | — | — | — | <-999% | <-999% | +158.8% | +45.8% | >999% | -100.0% | +100.0% | -100.0% | — | — | — | — |